Paramount’s action comedy Novocaine saw the brilliant Jack Quaid continue his strong 2025 run, following the late-January release of the widely acclaimed sci-fi thriller, Companion. Having just debuted in theaters across the most recent weekend,

Jack Quaid’s action-comedy “ Novocaine ” topped a painfully slow weekend at the box office with $8.7 million. For theater owners, however, there’s not too much to celebrate: It’s one of the worst debuts to still capture the No. 1 spot (at least since the pandemic ground moviegoing to a halt).

Novocaine could have been written by a 12-year-old, and I’m not sure I mean that pejoratively. It’s a riff on superhero stories, but it’s been thought up with a whiff of dopey plausibility: The film’s protagonist,

March 2025 was never going to be huge at the domestic box office. While this time last year saw the movie release calendar populated with titles including Denis Villeneuve's Dune: Part Two, Mike Mitchell's Kung Fu Panda 4,

Quaid's leading role in Novocaine feels like a natural continuation of these genre-bent everymen. He plays Nathan Caine, a mild-mannered assistant bank manager who has congenital insensitivity to pain with anhidrosis (CIPA), a genetic disorder that impacts his nervous system to the point that he can't feel pain or temperature.

“Novocaine” only cost $18 million to produce, so (like its main character) it shouldn’t be feeling any pain at the box office. On the flip side, “Mickey 17” cost $118 million to produce and needs around $275 million to $300 million worldwide to make a profit.

How far would you push your body if you couldn't feel any pain? Well, when it comes to love, the answer for Nathan Caine in "Novocaine" is: pretty dang far. Hitting theaters on Friday, "Novocaine" is both a rom-com and an action film,

Jack Quaid's action comedy film is looking to dethrone Mickey 17 at what might be the year's softest weekend at the box office so far.